292 related articles for article (PubMed ID: 6397984)
1. Platelet-vessel wall interactions: implication of 5-hydroxytryptamine. A review.
De Clerck F; van Nueten JM; Reneman RS
Agents Actions; 1984 Dec; 15(5-6):612-26. PubMed ID: 6397984
[TBL] [Abstract][Full Text] [Related]
2. Platelet-vessel wall interactions in hemostasis: implication of 5-hydroxytryptamine.
De Clerck F; Somers Y; Van Gorp L
Agents Actions; 1984 Dec; 15(5-6):627-35. PubMed ID: 6543415
[TBL] [Abstract][Full Text] [Related]
3. Adenine nucleotides, serotonin, and endothelium-dependent relaxations to platelets.
Houston DS; Shepherd JT; Vanhoutte PM
Am J Physiol; 1985 Mar; 248(3 Pt 2):H389-95. PubMed ID: 3156512
[TBL] [Abstract][Full Text] [Related]
4. Platelet-mediated vascular permeability in the rat: a predominant role for 5-hydroxytryptamine.
De Clerck F; Van Gorp L; Beetens J; Reneman RS
Thromb Res; 1985 May; 38(4):321-39. PubMed ID: 3160131
[TBL] [Abstract][Full Text] [Related]
5. Serotonin and the blood vessel wall.
Van Nueten JM
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S49-51. PubMed ID: 2412058
[TBL] [Abstract][Full Text] [Related]
6. Platelet-mediated vascular contractions: inhibition of the serotonergic component by ketanserin.
De Clerck F; Van Nueten JM
Thromb Res; 1982 Sep; 27(6):713-27. PubMed ID: 6817452
[TBL] [Abstract][Full Text] [Related]
7. Involvement of 5-HT(1B/1D) and 5-HT2A receptors in 5-HT-induced contraction of endothelium-denuded rabbit epicardial coronary arteries.
Ellwood AJ; Curtis MJ
Br J Pharmacol; 1997 Nov; 122(5):875-84. PubMed ID: 9384503
[TBL] [Abstract][Full Text] [Related]
8. Effects of ketanserin, a selective 5-HT2 serotonergic antagonist, on the secondary recruitment of human platelets in vitro.
De Clerck F; Xhonneux B
Agents Actions; 1986 Mar; 17(5-6):515-26. PubMed ID: 2939698
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist.
de Clerck F; David JL; Janssen PA
Agents Actions; 1982 Jul; 12(3):388-97. PubMed ID: 6215842
[TBL] [Abstract][Full Text] [Related]
10. Serotonin and the vascular system. Role in health and disease, and implications for therapy.
Houston DS; Vanhoutte PM
Drugs; 1986 Feb; 31(2):149-63. PubMed ID: 3512233
[TBL] [Abstract][Full Text] [Related]
11. The involvement of 5-HT2-receptor sites in the activation of cat platelets.
De Clerck F; Xhonneux B; Leysen J; Janssen PA
Thromb Res; 1984 Feb; 33(3):305-21. PubMed ID: 6710435
[TBL] [Abstract][Full Text] [Related]
12. Differential classification of vascular smooth muscle and endothelial cell 5-HT receptors by use of tryptamine analogues.
Leff P; Martin GR; Morse JM
Br J Pharmacol; 1987 Jun; 91(2):321-31. PubMed ID: 3607360
[TBL] [Abstract][Full Text] [Related]
13. Monocrotaline pyrrole-induced cardiopulmonary toxicity is not altered by metergoline or ketanserin.
Ganey PE; Sprugel KH; Hadley KB; Roth RA
J Pharmacol Exp Ther; 1986 Apr; 237(1):226-31. PubMed ID: 2937908
[TBL] [Abstract][Full Text] [Related]
14. Serotonergic receptor subtypes and vascular reactivity.
Van Nueten JM; Leysen JE; de Clerck F; Vanhoutte PM
J Cardiovasc Pharmacol; 1984; 6 Suppl 4():S564-74. PubMed ID: 6210424
[TBL] [Abstract][Full Text] [Related]
15. Effects of serotonin on platelets and blood vessels.
De Clerck F
J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S1-5. PubMed ID: 1717767
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of potent and selective S2-serotonergic antagonists.
Janssen PA
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S2-11. PubMed ID: 2412048
[TBL] [Abstract][Full Text] [Related]
17. Characterization of rat platelet serotonin receptors with tryptamine agonists and the antagonists: ketanserin and SCH 23390.
Killam AL; Cohen ML
Thromb Res; 1991 Nov; 64(3):331-40. PubMed ID: 1805448
[TBL] [Abstract][Full Text] [Related]
18. Can peripheral serotonergic blockade explain the hypotensive effect of ketanserin?
Vanhoutte PM
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S105-9. PubMed ID: 2412025
[TBL] [Abstract][Full Text] [Related]
19. Age and the platelet serotonin vasoconstrictor axis in essential hypertension.
Amstein R; Fetkovska N; Lüscher TF; Kiowski W; Bühler FR
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S35-40. PubMed ID: 2459512
[TBL] [Abstract][Full Text] [Related]
20. Serotonin-S2 receptor binding sites and functional correlates.
Leysen JE; de Chaffoy de Courcelles D; De Clerck F; Niemegeers CJ; Van Nueten JM
Neuropharmacology; 1984 Dec; 23(12B):1493-501. PubMed ID: 6396526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
